Triggering cell death in metastatic melanoma may pave the way for new cancer treatments

Rákkutatás · Melanoma

In metastatic melanoma cells that have spread to lymph nodes, the protein ferroptosis suppressor protein 1 (FSP1) provides a critical defense against cell death; inhibiting FSP1 with novel small‑molecule inhibitors sharply reduces tumor growth in vivo.

A study published in Nature used mouse models to demonstrate that metastatic melanoma cells that have entered lymph nodes rely on the antioxidant protein FSP1 to prevent ferroptosis, a form of cell death driven by lipid oxidation. By delivering new FSP1‑inhibiting compounds directly to the lymph‑node tumors, researchers observed a pronounced shrinkage in tumor growth, whereas the same inhibitors had little effect when tested on melanoma cells cultured in vitro. These findings highlight a previously underappreciated tissue‑context dependence of ferroptosis in cancer and suggest that targeting FSP1 could provide a therapeutic strategy against metastatic melanoma.

The discovery that metastatic melanoma cells in lymph nodes are uniquely dependent on FSP1 to evade ferroptosis offers a new vulnerability that can be exploited therapeutically. Targeting this pathway could slow the progression of metastatic disease and improve outcomes for patients whose cancer has spread to lymphatic tissue.

Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Eredeti forrás

Kapcsolódó jelek